Syndax Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
298
- Stock Symbol
-
SNDX
- Share Price
-
$8.72
- (As of Friday Closing)
Syndax General Information
Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Contact Information
Website
www.syndax.comCorporate Office
- 35 Gatehouse Drive
- Building D, Floor 3
- Waltham, MA 02451
- United States
Corporate Office
- 35 Gatehouse Drive
- Building D, Floor 3
- Waltham, MA 02451
- United States
Syndax Stock Performance
As of 20-Nov-2026, Syndax’s stock price is $8.72. Its current market cap is $785M with 90M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.72 | $9.13 | $8.41 - $25.59 | $785M | 90M | 2.61M | -$2.37 |
Syndax Financials Summary
As of 30-Sep-2026, Syndax has a trailing 12-month revenue of $290M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,376,281 | 1,391,623 | 739,675 | 1,471,052 |
| Revenue | 289,678 | 172,352 | 23,680 | 0 |
| EBITDA | (179,600) | (274,361) | (339,911) | (230,303) |
| Net Income | (209,483) | (285,422) | (318,758) | (209,360) |
| Total Assets | 692,671 | 529,706 | 724,816 | 612,880 |
| Total Debt | 245,320 | 1,523 | 14,174 | 1,635 |
Syndax Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Syndax Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Syndax Comparisons
Industry
Financing
Details
Syndax Competitors (115)
One of Syndax’s 115 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Imunon | Corporation | Lawrenceville, NJ | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Syndax Patents
Syndax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026183535-A1 | Aryl ether analogs comprising an ether link as inhibitors of the menin-mll interaction | Pending | 27-Feb-2025 | ||
| WO-2026183524-A1 | Benzamide aryl ether analogs comprising a 4,5-spiro ring system as inhibitors of the menin-mll interaction | Pending | 27-Feb-2025 | ||
| WO-2026183418-A1 | Benzamide aryl ether analogs comprising a direct link as inhibitors of the menin-mll interaction | Pending | 27-Feb-2025 | ||
| US-20260258053-A1 | Benzamide aryl ether analogs comprising an amine linker as inhibitors of the menin-mll interaction | Pending | 27-Feb-2025 | ||
| WO-2026183529-A1 | Benzamide aryl ether analogs comprising an amine linker as inhibitors of the menin-mll interaction | Pending | 27-Feb-2025 | C07D403/14 |
Syndax Signals
Syndax ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.34 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Syndax FAQs
-
When was Syndax founded?
Syndax was founded in 2005.
-
Where is Syndax headquartered?
Syndax is headquartered in Waltham, MA.
-
What is the size of Syndax?
Syndax has 298 total employees.
-
What industry is Syndax in?
Syndax’s primary industry is Drug Discovery.
-
Is Syndax a private or public company?
Syndax is a Public company.
-
What is Syndax’s stock symbol?
The ticker symbol for Syndax is SNDX.
-
What is the current stock price of Syndax?
As of 20-Nov-2026 the stock price of Syndax is $8.72.
-
What is the current market cap of Syndax?
The current market capitalization of Syndax is $785M.
-
What is Syndax’s current revenue?
The trailing twelve month revenue for Syndax is $290M.
-
Who are Syndax’s competitors?
Aura Biosciences, Dicerna Pharmaceuticals, Imunon, AB Science, and Agios Pharmaceuticals are some of the 115 competitors of Syndax.
-
What is Syndax’s annual earnings per share (EPS)?
Syndax’s EPS for 12 months was -$2.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process